Despair engulfs smaller device companies
The nightmare on the public markets is not confined to the bigger groups.
Big medtech's share price bloodbath
The worst half-year period for a decade leaves the biggest medical device companies half a trillion dollars poorer.
Few biopharma risers stand out at the half year
A look for winners and losers finds a sector laid low by poor sentiment and Covid fatigue, with Lantheus, Vertex and Jazz providing a few bright spots.
Are we there yet?
Second-quarter share price movements give another glimpse of the dire state of the markets, but there might be reasons for optimism.
The retrenchment begins for venture funding
The gloomy climate for biotech is now taking its toll on private companies too.
Medtech research spending set to slow in 2022
And some diagnostics groups are forecast to actually cut R&D outlay this year as the pandemic eases.
